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Abstract. Protein fibrillization is implicated in the pathogenesis of most, if not all, age-
associated neurodegenerative diseases, but the mechanism(s) by which it triggers neuronal
death is unknown. Reductionist in vitro studies suggest that the amyloid protofibril may be the
toxic species and that it may amplify itself by inhibiting proteasome-dependent protein
degradation. Although its pathogenic target has not been identified, the properties of the
protofibril suggest that neurons could be killed by unregulated membrane permeabilization,
possibly by a type of protofibril referred to here as the ‘amyloid pore ’. The purpose of this
review is to summarize the existing supportive circumstantial evidence and to stimulate further
studies designed to test the validity of this hypothesis.
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1. Introduction
A compelling circumstantial case can be made that amyloid ﬁbril formation is a primary cause of
neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD), prion diseases, and
related diseases (see Table 1) (Rochet & Lansbury, 2000 ; Stefani & Dobson, 2003). Supporting
evidence for this case, is derived from (1) pathology : ﬁbrillar protein aggregates often colocalize
with neuronal loss, (2) genetics : the gene encoding the ﬁbrillar protein is linked to disease
(autosomal dominant mutations cause familial disease, polymorphisms can be susceptibility
factors, and some haplotypes are linked to risk), (3) animal modeling : overexpression of
the ﬁbrillar protein reproduces many features of the human disease, and (4) biophysics :
proteins containing disease-associated mutations aggregate more rapidly than wild-type proteins.
However, the mechanism by which amyloid ﬁbril formation causes neurodegeneration and the
identity of the pathogenic species have not been determined. It is not possible to directly observe
the pathogenic event. Therefore, one is left to extrapolate from simpliﬁed models in order
to produce a working hypothesis, which can then be tested experimentally. The design of a
successful therapeutic strategy based on a working hypothesis will be taken as a ‘proof ’ of its
veracity.
The pathogenic pathway is likely to be much more complicated than an evolutionarily
optimized process like, say, ribosome assembly. Furthermore, there is no a priori reason to
assume that cell death in neurodegenerative disease occurs by a single mechanism or that, if
protein aggregates are responsible, a single species is capable of acting alone as the pathogenic
trigger. Despite these caveats, this review will apply Occam’s razor and start with the working
hypothesis that a single species of protein aggregate may be responsible for initiating a cascade
of events that culminate in neurodegeneration. It is our hope that this review will stimulate
others to design experiments to test the relevance, or lack of thereof, of this working hypothesis.
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The majority of research in the ﬁeld of neurodegeneration has focused on the cause of
neuronal death, rather than on the identity of the neurotoxic species. This review will focus on
in vitro studies aimed at the characterization of an intermediate on the amyloid pathway as one
potential toxic species. This review is based on the premise that understanding the structures of
the protein aggregates and the dynamics of their interconversion in vitro, can establish potential
links between aggregation and toxicity. The key to such an approach is to allow genetic
information, especially regarding autosomal dominant (gain of function) mutations, to guide
these experiments. Before summarizing these studies, it is important to emphasize that any
reductionist approach must ultimately explain essential features of the in vivo process that it is
seeking to elucidate. In the case of neurodegeneration, these are :
(1) Aging is one of the strongest susceptibility factor for all of the neurodegenerative diseases.
Even those that are purely genetic, like Huntington’s disease, are primarily adult-onset. This
does not necessarily mean that the pathogenic process takes a long time, but only that
neurons become more susceptible to occurrence of a pathogenic event as they age.
(2) All of these diseases show selectivity to particular types of neurons (hence the diverse
symptoms).
(3) Mutations cause early-onset forms of these diseases that are transmitted in an autosomal
dominant manner.
Points (2) and (3) are linked, since diﬀerent mutations in the same protein can produce distinct
clinical entities that aﬀect diﬀerent neuronal subpopulations (three examples are fatal insomnia,
which results from a point mutation in the prion protein (Gambetti et al. 1995), hereditary
cerebral haemorrhage with amyloidosis of the Dutch type, caused by a mutation in amyloid
precursor protein (APP)/Ab (Maat-Schieman et al. 1992), and dementia with Lewy bodies,
caused by a mutation in a-synuclein (Zarranz et al. 2004)).
Several lines of evidence suggest that in vitro amyloid ﬁbril formation mimics the in vivo pro-
cess : (a) ﬁbrils formed in vitro strongly resemble those in diseased tissues (Sunde et al. 1997),
(b) protoﬁbrillar intermediates, ﬁrst detected in vitro, and later in vivo (see Table 1) exhibit strik-
ingly similar structural and neurotoxic properties (Roher et al. 1996) and (c ) the speciﬁcity of
in vitro assembly is reﬂected in vivo (Wetzel, 1994 ; Helms & Wetzel, 1996 ; Rajan et al. 2001 ;
Kheterpal et al. 2003). Taken together, these observations suggest that structural and mechanistic
clues derived from in vitro studies are relevant to the role of protein ﬁbrillogenesis in neuro-
degenerative diseases and may provide molecular targets for the design of desperately needed
therapeutic agents.
2. What is the significance of the shared structural properties of
disease-associated protein fibrils?
Approximately 24 human proteins form amyloid ﬁbrils in vivo (Stefani & Dobson, 2003). These
proteins are unrelated at the level of primary structure, consistent with the ﬁnding that many
proteins with no connection to disease can form amyloid ﬁbrils with a common core structure
in vitro, suggesting that the amyloid ﬁbril is an intrinsically stable structure (Dobson, 2001).
Amyloid ﬁbrils are not crystalline, so their structural similarity is based on lower-resolution
approaches : X-ray ﬁbril diﬀraction, electron and atomic force microscopy, and their ability to
bind histopathological dyes like Congo Red and Thioﬂavin T (Sunde et al. 1997). The structural
convergence among various amyloid ﬁbrils is also corroborated by the ﬁndings that antibodies
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Table 1. A summary of studies examining the structure and formation of protoﬁbrils, including amyloid pores by several amyloid-forming priteins in vitro, cell cultures and
in vivo grouped according to the amyloid disease to which they are relevant. Due to space limitations only the most relevant references are cited
Disease
Amyloid-forming
proteins and peptides
Evidence for
protoﬁbrils in vitro
Evidence for protoﬁbrils
In cell culture and in vivo
Evidence for annular
structures/amyloid pores
Evidence for
channel/pore activity
Alzheimer’s
disease
Ab 1-40 (WT) Goldsbury et al. 2005 ;
Harper et al. 1997a, b,
1999; Huang et al. 2000 ;
Kayed et al. 2004 ;
Lambert et al. 1998 ; Stine
et al. 2003 ; Walsh et al.
1997, 1999; Yong et al.
2002)
Funato et al. 1999 ; Gong
et al. 2003 ; Kuo et al. 1996 ;
Lambert et al. 2001 ;
Pitschke et al. 1998 ;
Roher et al. 1996
Hafner et al. 2001 ; Kayed
& Glabe, 2004; Klug et al.
2003 ; Lashuel et al. 2002b,
2003
Alarcon et al. 2006 ; Arispe
et al. 1993a, b, 1994, 1996;
Kagan et al. 2002 ;
Kawahara & Kuroda,
2000, 2001; Kawahara
et al. 2000 ; Kourie et al.
2001b; Lin et al. 1999 ;
Singer & Dewji, 2006
Ab 1-40 (E22G) Dahlgren et al. 2002 ;
Lashuel et al. 2002b, 2003;
Nilsberth et al. 2001
Morishima-Kawashima
& Ihara, 1998 ; Podlisny
et al. 1995 ; Walsh et al.
2000, 2002
Lashuel et al. 2002b, 2003
Ab 1-42
(WT & E22G)
Dahlgren et al. 2002 ;
El-Agnaf et al. 2000 ;
Parbhu et al. 2002 ; Roher
et al. 1996 ; Stine et al.
2003 ; Wang et al. 2002a
Chromy et al. 2003 ; Kayed
et al. 2004 ; Lashuel et al.
2003 ; Lin et al. 2001
Bahadi et al. 2003a ; Bhatia
et al. 2000 ; Hirakura et al.
1999 ; Lin et al. 2001 ; Rhee
et al. 1998
Parkinson’s
disease
a-Synuclein (WT, A53T
& A30P)
Cappai et al. 2005 ; Conway
et al. 2000, 2001; Ding et al.
2002 ; Kaylor et al. 2005 ;
Lashuel et al. 2002a ;
Rochet et al. 2000 ;
Shtilerman et al. 2002 ;
Volles & Lansbury, 2003;
Zhu & Fink, 2003
El-Agnaf et al. 2006 ; Feany
& Bender, 2000; Gosavi
et al. 2002 ; Lee & Lee,
2002; Lee et al. 2002 ; Lo
Bianco et al. 2002 ; Masliah
et al. 2000 ; Sharon et al.
2001, 2003a, b.
Lashuel et al. 2002a, b ;
Ding et al. 2002 ;
Shtilerman et al. 2002 ;
Rochet et al. 2000 ; Zhu &
Fink, 2003 ; Crystal et al.
2003 ; Pountney et al.
2004 ; Zhu et al. 2004 ;
Lowe et al. 2004 ; Quist
et al. 2005
Volles & Lansbury, 2002;
Volles et al. 2001
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Familial British
dementia
ABri El-Agnaf et al. 2001a, b ;
Srinivasan et al. 2003
Holton et al. 2001 Srinivasan et al. 2003 Quist et al. 2005
Dialysis-associated
amyloidosis
b2-Microglobulin Kad et al. 2003 Kayed & Glabe, 2004 Hirakura & Kagan, 2001
Secondary systemic
amyloidoses
Serum amyloid A Wang et al. 2002b Wang et al. 2002b Hirakura et al. 2002
Prion-related
diseases
MHM2 PrP 106 (D23-88
and D141-176)
Baskakov et al. 2000 Riesner et al. 1996 ;
Supattapone et al. 1999
Kawahara et al. 2000 ;
Kourie, 2002; Kourie &
Culverson, 2000;
Kourie et al. 2001a, 2003 ;
Lin et al. 1997
Prion, PrP 106-126 Kayed & Glabe, 2004 Kayed & Glabe, 2004
84-146 Sokolowski et al. 2003
SHa PrP (90-232) Baskakov et al. 2002 ;
Lu & Chang, 2002;
Vendrely et al. 2005
Sokolowski et al. 2003 Hirakura et al. 2000b
PrP (23-231) Bahadi et al. 2003b, c
Huntington’s
disease
(polyglutamine) Poirier et al. 2002a Kayed & Glabe, 2004 Hirakura et al. 2000a ;
Kagan et al. 2001 ;
Monoi et al. 2000
Demuro et al. 2005 ;
Kayed et al. 2004
Amyotrophic lateral
sclerosis
Superoxide dismutase-1
(WT & A4V, G37R,
G85R)
Chung, 2003; Rakhit et al.
2002, 2004; Ray et al. 2004
Turner et al. 2003 Chung, 2003; Ray et al.
2004
Senile & familal
amyloidosis
Transthyretin Cardoso et al. 2002a, b ;
Kayed et al. 2003, 2004 ;
Lashuel et al. 1998, 1999
Sousa et al. 2001, 2002 ;
Teng et al. 2001
Kayed & Glabe, 2004 Azimov et al. 2001
Type II diabetes IAPP Anguiano et al. 2002 ; Green
et al. 2003 ; Green, 2004;
Kayed & Glabe, 2004;
Kayed et al. 2003 ; Porat
et al. 2003 ; Rhoades &
Gafni, 2003
Butler et al. 2003 ;
de Koning et al. 1994 ;
Janson et al. 1996 ;
O’Brien et al. 1994
Janson et al. 1999 ;
Anguiano, 2002 ;
Kayed & Glabe, 2004 ;
Porat et al. 2003
Anguiano et al. 2002 ;
Harroun et al. 2001 ;
Hirakura et al. 2000b;
Kawahara et al. 2000 ;
Mirzabekov et al. 1996 ;
Porat et al. 2003
P53 Ishimaru et al. 2003 Ishimaru et al. 2003
Equine lysozyme Malisauskas et al. 2003 Malisauskas et al. 2003
Insulin Dzwolak et al. 2005 Dzwolak et al. 2005
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raised against the ﬁbrillar form of the amyloidogenic protein amyloid-b (Ab ) recognize
amyloid ﬁbrils derived from other amyloid-forming proteins (O’Nuallain & Wetzel, 2002).
The shared conformational epitopes have not been identiﬁed, but may be involved in patho-
genesis. Moreover, the structural similarities suggest a shared mechanism of amyloid ﬁbril
formation.
2.1 Mechanism of amyloid fibril formation in vitro
2.1.1 In vitro fibril formation involves transient population of ordered aggregates of
intermediate stability, or protofibrils
In order to form an amyloid ﬁbril, proteins must adopt a b-sheet rich conformation(s). This
may involve induction of structure in a disordered monomer, or the partial unfolding of a
b-sheet-containing globular protein. The b-sheet-rich species has a high propensity to aggregate/
ﬁbrillize (Kelly, 1998). In vitro amyloid ﬁbril formation does not proceed via a simple two-state,
‘ intermediate-less ’ mechanism akin to microtuble formation from tubulin (these processes have
evolved to be eﬃcient and non-toxic), although that model can be instructive ( Jarrett &
Lansbury, 1993). Rather, discrete b-sheet rich oligomeric intermediates appear before ﬁbrils
form and disappear upon ﬁbril formation (Harper et al. 1997a ; Walsh et al. 1997 ; Lambert et al.
1998) (Fig. 1). These are collectively designated protoﬁbrils. Protoﬁbrils are more stable than
the monomer, but less stable than the ﬁbrillar product. They appear to be obligate intermediates
in ﬁbril formation ; the transient formation of protoﬁbrils has been observed in every well-
characterized in vitro case, suggesting that they are obligate intermediates that are likely to exist,
albeit transiently, in vivo.
Oligomers
Monomer-dimer-tetramer
α-Synuclein
ABri
Spherical Chain-like Annular
n Protofibrils
Amyloid fibrils
Plaques
Lewy bodies
Fig. 1. In vitro ﬁbril formation involves transient population of ordered aggregates, or protoﬁbrils.
Schematic representation summarizing the quaternary structural species populated during amyloid ﬁbril
formation in vitro and are thought to form during protein ﬁbrillogenesis and deposition in vivo. For simplicity,
only the most commonly observed (globular, chain-like and annular structures) protoﬁbrillar structures are
shown. (The ABri images were kindly provided by Dr Michael Zagorski.)
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3. Toxic properties of protofibrils
3.1 Protofibrils, rather than fibrils, are likely to be pathogenic
The presence of amyloid ﬁbrils in the post-mortem brains of demented patients led to the ﬁrst
description of AD and resulted in the hypothesis that ﬁbrils themselves are the primary patho-
genic species. This hypothesis fails to explain several important pathological and clinical
characteristics of AD, raising the possibility that a species other than amyloid ﬁbrils could be the
toxic species (Goldberg & Lansbury, 2000). First, there is no correlation between the amounts of
ﬁbrillar Ab deposits at autopsy and the clinical severity of AD (Lemere et al. 1996 ; Terry et al.
1991). Such a correlation does exist between ‘soluble Ab ’ (monomers plus protoﬁbrils) in the
brain and early cognitive dysfunction (Lue et al. 1999 ; McLean et al. 1999 ; Naslund et al. 2000).
Second, transgenic animals that overproduce APP exhibit neuronal and behavioral abnormalities
before amyloid plaques can be detected (Chui et al. 1999 ; Hsia et al. 1999 ; Moechars et al. 1999 ;
Mucke et al. 2000). Third, inhibiting Ab amyloid ﬁbril formation does not necessarily attenuate
Ab-associated toxicity towards cultured neurons (Aksenova et al. 1996 ; Stege et al. 1999). Fourth,
one autosomal dominant form of AD results from a mutation [APP (E693G)=Ab (E22G)] that
decreases Ab production in vivo and promotes protoﬁbril formation and toxicity in vitro
(Nilsberth et al. 2001 ; Lashuel et al. 2003 ; Whalen, 2005). Fifth, in some AD transgenic mice,
vaccination with an Ab-directed antibody prevented or reversed age-dependent memory decline
without reducing the amyloid burden (Morgan et al. 2000) [in other cases, vaccination has been
shown to reduce behavioral and cognitive deﬁcits and the amyloid burden ( Janus et al. 2000 ;
Morgan et al. 2000)]. Finally, Ab aggregates with properties that are indistinguishable from Ab
protoﬁbrils formed in vitro have been found in human CSF, human cerebral cortex (McLean et al.
1999), and in neuritic amyloid plaques from AD brains (Roher et al. 1996), raising the possibility
that soluble preﬁbrillar oligomeric species, rather than the ﬁbrils, could be the pathogenic species
in AD and related amyloid diseases. Consistent with this hypothesis, oligomeric (dimer, trimers
and tetramers) low-molecular-weight oligomers (Walsh et al. 2002 ; Wang et al. 2004; Cleary et al.
2005 ; Townsend et al. 2006) and protoﬁbrillar forms of Ab altered neuronal function and/or
caused neuronal death in culture (Lambert et al. 1998 ; Hartley et al. 1999 ; Walsh et al. 2002 ;
Whalen et al. 2005).
The toxic protoﬁbril hypothesis also explains features of PD and other neurodegenerative
diseases that are inconsistent with the ﬁbril being the pathogenic species (Goldberg & Lansbury,
2000 ; Caughey & Lansbury, 2003 ; Silveira et al. 2005). In PD, ﬁbrillar intraneuronal inclusions
comprising a-synuclein, known as Lewy bodies (LBs), are an invariant feature of sporadic and
autosomal dominant forms of PD, but are absent in autosomal recessive juvenile Parkinsonism
(AJRP) (Shimura et al. 2001). It is likely that AJRP brains have such high levels of protoﬁbrils that
complete neurodegeneration occurs before LBs have a chance to form [AJRP results from a
deletion in the parkin gene ; point mutations produce a later-onset form of PD that is charac-
terized by LBs (Kitada et al. 1998)]. Elevated levels of soluble oligomeric forms of a-synulcien
have been detected in plasma samples of PD patients compared to controls (El-Agnaf et al.
2006). Similarly, transgenic mice that overexpress the human a-synuclein protein become
symptomatic (movement disorder plus dopaminergic abnormalities) but do not produce ﬁbrillar
deposits (Masliah et al. 2000). Furthermore, virus-mediated overexpression of human a-synuclein
into the substantia nigra of rats (Kirik et al. 2002 ; Lo Bianco et al. 2002) and primates (Kirik et al.
2003) results in selective dopaminergic neuronal death with non-ﬁbrillar, a-synuclein-containing
inclusions. In vitro studies of a-synuclein aggregation provide possible hints as to the underlying
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situation : mixtures of human and mouse a-synuclein (as exist in the transgenic mouse brain)
accumulate protoﬁbrils, but ﬁbrillize very slowly (Rochet et al. 2000). Interestingly, virus-
mediated expression of rat a-synuclein in rat brain results in aggregation, but no neuro-
degeneration (Kirik et al. 2002 ; Lo Bianco et al. 2002). Further characterization of the aggregates
formed by human and rat a-synuclein could provide important insights into the role of
a-synuclein aggregation in the degeneration of dopaminergic neurons.
Other neurodegenerative diseases fail to support the proposal that amyloid ﬁbrils are patho-
genic. Prion protein (PrP) ﬁbrils are observed in some prion diseases, but are not an invariant
feature (Chiesa & Harris, 2001). In yeast and mouse models of prion disease, toxicity was
produced in the absence of the stable, protease-resistant aggregated form of the prion protein
(PrP-Sc) (Ma & Lindquist, 2002 ; Ma et al. 2002). A transgenic mouse model of a familial prion
disease became symptomatic before PrP-Sc could be detected (Chiesa et al. 2003). Recent studies
by Caughey and co-workers suggest that the most infectious PrP particles represent protoﬁbrillar
particles with molecular masses ranging from 300–600 kDa (corresponding to 14–28 PrP
molecules) (Silveira et al. 2005). Finally, in systemic amyloid diseases, where amyloid was thought
to produce disease by physically interfering with organ function, studies by Reixach et al. suggest
a primary pathogenic role for protoﬁbrils in initiating cytotoxicity and organ dysfunction
(Reixach et al. 2004). For example, non-ﬁbrillar aggregates of transthyretin (TTR), a protein
associated with systemic amyloidosis and familial amyloid polyneuropathy (FAP), have been
detected in transgenic mice expressing wild-type and mutant TTR (Teng et al. 2001) and in the
nerves of FAP patients (Sousa et al. 2001, 2002). These aggregates were linked to signiﬁcant
clinical pathology early in the disease before the ﬁbrillar deposits could be detected.
3.2 The toxic protofibril may be a mixture of related species
In an eﬀort to more precisely identify the neurotoxic protein aggregate, cell culture models of
extracellular toxicity have been utilized. Although these simpliﬁed models allow more detailed
analysis, their relevance to AD is debatable. Given that caveat, as well as the fact that Ab
oligomers added to cell culture media are heterogeneous (Lashuel et al. 2003; Goldsbury et al.
2005) and are likely to change during the course of an experiment, there is remarkable agreement
among these studies that the protoﬁbril, and not the monomer or the ﬁbril, is a toxic entity
(Lambert et al. 1998 ; Hartley et al. 1999 ; White et al. 2005 ; Townsend et al. 2006). In the case of
Ab, the amyloid protein of AD, globular oligomers (designated ADDLs) were toxic to cultured
neurons (Lambert et al. 1998) and inhibited hippocampal long-term potentiation (LTP) when
introduced to brain slices (Wang et al. 2002a). Globular oligomers of similar sizes (based on AFM
and EM measurement) have been described by other research groups and were shown to be
toxic to cultured neurons (Barghorn et al. 2005). In a related study, small spherical and chain-like
Ab protoﬁbrils (but not monomer, dimer, trimer) induced acute electrophysiological changes
and progressive neurotoxicity in cortical neurons (Hartley et al. 1999). Large spherical aggregates
of Ab (average diameter of >10 nm), termed amylospheroids, exhibited signiﬁcantly higher
toxicity than small spherical Ab oligomers (<10 nm) (Hoshi et al. 2003). Ab42 forms spherical
aggregates (diameter>10 nm) more rapidly and exhibits signiﬁcantly more (>100-fold) toxicity
to neuronal cultures than those formed by Ab40. Similar, apparently spherical structures with
diameters ranging from 8–24 nm have also been observed as transient intermediates during the
ﬁbrillogenesis of the arctic variant (E22G) of Ab40 and Ab42 (Lashuel et al. 2003), a-synuclein
(Lashuel et al. 2002a) and mutant SOD1 (Ray et al. 2004). The toxicity of TTR towards cultured
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cells is also linked to a non-ﬁbrillar oligomeric species, possibly an octamer (Reixach et al. 2004).
Finally, it is probable that the protoﬁbril structure, rather than the protein primary sequence,
produces toxicity. For example, small spherical protoﬁbrils, formed in vitro by an amyloidogenic
SH3 domain from bovine phosphatidyl-inositol-3 kinase (which is not linked to any disease)
are toxic to cultured cells (Bucciantini et al. 2002).
3.3 Morphological similarities of protofibrils suggest a common mechanism of toxicity
The shared morphological and toxic properties of amyloid protoﬁbrils suggest that toxicity
depends on shared structural features. Consistent with this hypothesis, antibodies raised against
protoﬁbrillar Ab were reported to recognize protoﬁbrillar species derived from other amyloi-
dogenic proteins (e.g. a-synuclein, polyglutamine, TTR, IAPP, lysozyme, human insulin, and
PrP106-126), but not monomeric or ﬁbrillar forms of these proteins (Kayed et al. 2003). These
antibodies also inhibit the toxicity of these proteins. These ﬁndings support detailed structural
studies of protoﬁbrils, some of which are summarized below. Furthermore, These observations
raise the possibility that these diverse (with respect to sequence, at least) structures may exert
their toxicity through common mechanisms. It may be that an intermediate on the assembly
pathway that is in equilibrium with the protoﬁbril could be the toxic species. The most likely
candidates are low-molecular-weight oligomers (e.g. dimers, trimers or tetramers) or a high-
molecular-weight protoﬁbrillar species, most likely the 4 nm (¡1 nm) spherical species. This is
consistent with biophysical studies (AFM and EM) demonstrating that these spheres are the
precursors to the chain-like and annular protoﬁbrillar structures and appear to exist in equilib-
rium with the large spherical aggregates (8–70 nm). Several laboratories have demonstrated that
these species are capable of self-assembling into pore-like structures on artiﬁcial or biological
membranes (Lin et al. 2001 ; Ding et al. 2002).
3.4 Are the amyloid diseases a subset of a much larger class of previously unrecognized
protofibril diseases ?
The hypothesis that small protoﬁbrillar aggregates are pathogenic has an interesting corollary :
there may be many other diseases that, like ARJP, are not characterized by easily detected protein
aggregates. Unlike ARJP, which is genetically and clinically linked to the amyloid disease PD,
these diseases may not be recognized as involving protein aggregation at all. In contrast to our
expectation that the primary sequence eﬃciently directs protein folding, a signiﬁcant portion
of newly synthesized proteins (y35%) are not correctly folded in vivo (Schubert et al. 2000).
We expect that many more protein aggregation-driven pathologies remain to be discovered.
3.5 Fibrils, in the form of aggresomes, may function to sequester toxic protofibrils
According to the toxic protoﬁbril hypothesis, the role of the amyloid ﬁbril is uncertain ; it could
have some greatly reduced toxicity, it could be inert, or it could protect neurons by sequestering
toxic protoﬁbrils and/or by consuming protein monomers, inhibiting continued protoﬁbril
formation (Caughey & Lansbury, 2003). There is circumstantial evidence that ﬁbrils may have
a protective function. In PD brains, dopaminergic neurons that contain LBs appear to be
‘healthier ’ than neighboring neurons based on morphological and biochemical criteria
(Tompkins & Hill, 1997). Several transgenic models of polyglutamine diseases are characterized
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by polyglutamine inclusions in healthy neuron populations, but not in vulnerable neurons
(Kuemmerle et al. 1999). In a transgenic mouse model of one polyglutamine disease, spino-
cerebellar ataxia-type1 (SCA1), there was a direct correlation between the ability of neurons to
sequester ataxin-1 into inclusions and their resistance to cell death (Watase et al. 2002). Taken
together, these observations suggest that formation of ﬁbrillar inclusions may protect neurons
against protoﬁbril-induced neurotoxicity. There is mounting evidence that the sequestration
process may be an active one. Expression of any one of the four disease-associated proteins ;
cystic ﬁbrosis transmembrane conductance regulator (CFTR, associated with cystic ﬁbrosis)
( Johnston et al. 1998), SOD1 (amyotrophic lateral sclerosis) ( Johnston et al. 2000), the androgen
receptor (AR, X-linked spinobulbar muscular atrophy) (Taylor et al. 2003), or Parkin ( Junn et al.
2002) in cultured cells under conditions of oxidative stress or proteasome impairment leads to
sequestration of the mutant protein within multicomponent proteinaceous inclusions known as
aggresomes. Sequestration is actively mediated by microtubules ( Johnston et al. 1998). In the case
of Parkin, these inclusions exhibit morphological and immunohistochemical features similar
to LBs (Junn et al. 2002). In addition to sequestering toxic protein aggregates, aggresomes may
play an active role in facilitating the clearance of these toxic species by lysosomal mediated
degradation mechanisms (Taylor et al. 2003).
4. Amyloid pores, a common structural link among protein aggregation
neurodegenerative diseases
4.1 Mechanistic studies of amyloid fibril formation reveal common features, including
pore-like protofibrils
The convergent circumstantial evidence implicating protoﬁbrils as pathogens has motivated a
more detailed analysis of protoﬁbril structure and formation in vitro. These studies are brieﬂy
summarized below and in Table 1, grouped according to the amyloid disease to which they are
relevant. Similar pathways are followed by other ﬁbrillogenic proteins that are not known to be
related to disease (see Table 1 and below).
4.1.1 Amyloid-b (Ab) (Alzheimer’s disease)
Alzheimer’s disease (AD) is characterized by the presence of extracellular ﬁbrillar amyloid
plaques and intraneuronal neuroﬁbrillary tangles in brain areas associated with memory and
learning. The main ﬁbrillar constituent of amyloid plaques is amyloid-b (b(Glenner & Wong,
1984), a 39-42 amino acid peptide that is produced by endoproteolytic processing of the APP
(Selkoe, 1994). A central role for Ab amyloid ﬁbril formation in the etiology of AD is supported
by extensive genetic and biochemical evidence (Hardy & Selkoe, 2002). In solution, Ab
is unstructured, but Ab protoﬁbrils, including spherical (average diameter of 24–45 nm,
containingy40 monomers) and chain-like protoﬁbrils and are rich in b-sheet structure (Fig. 1)
(Harper et al. 1997a, b ; Walsh et al. 1997 ; Lambert et al. 1998 ; Parbhu et al. 2002 ; Stine et al. 2003).
Smaller oligomers (e.g. dimers, trimers and tetramers) likely exist, but are not populated in
solution (they can only be observed by SDS–PAGE). Once the critical concentration of the
spherical and later chain-like species is reached, they are rapidly converted into amyloid ﬁbrils. In
addition to the globular and chain-like protoﬁbrils, annular structures with variable diameters
(outer diameter 6–9 nm, inner diameter 15–2 nm) have also been observed during the
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ﬁbrillogenesis of Ab in vitro (Fig. 2a) and during the reconstitution of Ab in lipid bilayers (Fig. 3a)
(Hafner et al. 2001 ; Lin et al. 2001 ; Chromy et al. 2003 ; Klug et al. 2003; Lashuel et al. 2003 ; Kayed
& Glabe, 2004). The similar heights of the spheres, chain-like and annular protoﬁbrils suggests
that the spheres are the precursors of the others (Lashuel et al. 2003). Formation of annular
protoﬁbrils is promoted by a pathogenic mutation [APP (E693G)=Ab(E22G)] that is linked to
familial AD and accelerates the oligomerization of Ab in vitro (Nilsberth et al. 2001 ; Lashuel et al.
2002a, b). Annular protoﬁbrils represent only a small fraction of the total population of Ab
(a) Aβ
Arctic (E22G)
(b) Aα-Synuclein
A53T
(d)
A30P
(e)
ABri Equin
Lysozyme
IAPP SAA
(c) SOD
A4V
Fig. 2.Many amyloid proteins form annular pore-like protoﬁbrils and have channel- or pore-like properties
in vitro. Annular pore-like structures with variable diameters form during the in vitro ﬁbrillogenesis of disease
associated mutants of Ab [Arctic variant (E22G) of Ab40] (a, f ), a-synuclein (A53T & A30P) (b, d ), and
SOD1 (A4V) (c), and other amyloid-forming proteins (e).
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protoﬁbrils at any given time, which explains why these structures were missed or ignored in
previous studies.
4.1.2 a-Synuclein (PD and diffuse Lewy body disease)
PD is associated with the formation of intraneuronal ﬁbrillar inclusions (LBs) (Pollanen et al.
1993 ; Shults, 2006). a-Synuclein is the primary component of LBs in all PD patients (Spillantini
et al. 1998b) and is strongly implicated as a cause of PD by biochemical (Cookson, 2005) and
genetic studies of familial forms of PD (Polymeropoulos et al. 1997 ; Kruger et al. 1998 ; Singleton
et al. 2003 ; Zarranz et al. 2004) and by mouse (Masliah et al. 2000) and Drosophila (Feany &
Bender, 2000 ; Chen & Feany, 2005) modeling studies. Three diﬀerent a-synuclein missense
mutations (A30P, A53T and E46K) are associated with rare, autosomal dominant forms of early-
onset PD (Polymeropoulos et al. 1997 ; Kruger et al. 1998 ; Zarranz et al. 2004). In addition,
triplication of the wild-type a-synuclein gene causes autosomal dominant PD in an Iowan
(a) (c)
Aβ (1–40)
α -synuclein
ABri
ADan
Amylin
SAA
(b)
1. 50.000 mm/div
2. 15.000 mm/div
mm
50
100
150
200
Fig. 3. Amyloid forming proteins form pore-like/channel structures on artiﬁcial as well as biological
membranes. (a) AFM images of pore-like structures formed during the reconstitution of Ab in lipid bilayers
(adapted from Lin et al. 2001). (b) Pore-like structures that were obtained by incubating predominantly
spherical a-synuclein protoﬁbrils (WT and A53T) with brain-derived vesicles (adapted from Ding et al.
2002). (c) Amyloid-forming proteins/peptides reconstituted in lipid bilayers form pore/channel-like struc-
tures (adapted from Quist et al. 2005).
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kindred (Singleton et al. 2003). Transgenic mice (Masliah et al. 2000) expressing human wild-type
a-synuclein and Drosophila (Feany & Bender, 2000 ; Chen & Feany, 2005) expressing WT, A30P,
or A53T are characterized by a-synuclein non-ﬁbrillar (mice and ﬂy) or ﬁbrillar (Flynn &
Theesen, 1999) inclusions and a Parkinsonian phenotype. Like Ab, a-synuclein is not folded
under ‘native ’ conditions (Weinreb et al. 1996), but will form b-sheet rich protoﬁbrils and
amyloid ﬁbrils in vitro. Three mutations (A53T, E46K and A30P) linked to early-onset PD
promote the formation of a-synuclein protoﬁbrils, but the A30P mutation was shown to form
ﬁbrils more slowly than WT a-synuclein, suggesting that a-synuclein protoﬁbrils may cause
neurodegeneration in PD (Conway et al. 1998 ; Conway et al. 2000 ; El-Agnaf et al. 1998 ; Li et al.
2001 ; Pandey et al. 2006). Amyloid ﬁbril formation by a-synuclein occurs by a hierarchical
assembly mechanism (random coilpspherespchain-like and annular protoﬁbrilspﬁbrils)
similar to that observed for Ab in AD (Conway et al. 2000 ; Ding et al. 2002). The PD-linked
mutations promote formation of annular and tubular protoﬁbrillar structures (wild-type
a-synuclein forms annular protoﬁbrils after extended incubation) (Conway et al. 2000 ; Ding et al.
2002 ; Lashuel et al. 2002a, b) (Fig. 2b, d ). The diameter of a-synuclein annular protoﬁbrils
detected in vitro is similar to that of the a-synuclein ﬁbrils. Zhu and colleagues observed the
formation of a-synuclein annular protoﬁbrils during drug-induced disaggregation of a-synuclein
ﬁbrils in vitro (Zhu et al. 2004), suggesting that a direct relationship between the two structures
may exist. These observations are consistent with cross-sectional analysis of ex vivo amyloid ﬁbrils
demonstrating that amyloid ﬁbrils have an electron-lucent center, indicative of the presence of
a hollow center (Serpell et al. 2000).
4.1.3 ABri (familial British dementia)
ABri is the major component of amyloid deposits in the brain of patients with familial British
dementia (FBD). FBD is an autosomal dominant neurodegenerative disorder associated with a
stop codon mutation in the BRI gene that results in the production of ABri (Vidal et al. 1999 ;
Ghiso et al. 2000). In vitro ﬁbrillogenesis of ABri produced protoﬁbrils and subsequently, amyloid
ﬁbrils (El-Agnaf et al. 2001a, b ; Srinivasan et al. 2003, 2004), by a mechanism that is reminiscent
of that of Ab and a-synuclein, including the formation of spherical, chain-like and annular
protoﬁbrillar intermediates. Spherical protoﬁbrils exhibited more toxicity to cultured neurons
than chain-like protoﬁbrils and ﬁbrils (El-Agnaf et al. 2001a). Annular ABri protoﬁbrils
have been characterized in vitro (see Fig. 2e) (Srinivasan et al. 2004 ; O. M. El-Agnaf, personal
communication) but their toxicity has not been determined.
4.1.4 Superoxide dismutase-1 (amyotrophic lateral sclerosis)
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease (Rosen, 1978 ; Julien,
2001), is linked to the gene encoding superoxide dismutase-type 1 (SOD1) (Rosen et al. 1993 ;
Brown, 1997). Cytoplasmic inclusions containing mutant SOD1 are present in the motor
neurons of familial ALS patients (Shibata et al. 1996) and transgenic mouse models (Bruijn et al.
1998 ; Watanabe et al. 2001). Signiﬁcantly, these inclusions do not clearly contain ﬁbrillar sub-
structure. SOD1 is a structured homodimer. FALS mutations destabilize the native SOD1 dimer
(Nakano et al. 1996 ; Cardoso et al. 2002b; Hayward et al. 2002 ; Lindberg et al. 2002 ; Rodriguez
et al. 2002 ; Tiwari & Hayward, 2003 ; Rakhit et al. 2004 ; Ray et al. 2004) and promote SOD1
aggregation in vitro (Ray et al. 2004). Signiﬁcantly, SOD1 has not been induced to form amyloid
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ﬁbrils in vitro. Instead, spherical and annular oligomeric structures have been observed (Chung,
2003 ; Ray et al. 2004). As expected, the pathogenic SOD1 mutants aggregate more rapidly than
WT SOD1 (Chung, 2003 ; Ray et al. 2004), consistent with what is observed with Ab and
a-synuclein (Lashuel et al. 2003 ; Lashuel et al. 2002a, b). Their ﬁndings suggest that common
pathogenic assemblies may underlie all of these diseases. In addition to pathogenic mutations,
conditions that promote metal depletion or oxidative damage of SOD1 accelerate the formation
of annular structures by mutants and wild-type SOD (A4V, H46R, G37R, and G85R) (Chung,
2003 ; Elam et al. 2003 ; Ray et al. 2004). The morphology of these oligomeric forms of SOD1
formed in vitro resembles that of protoﬁbrillar species of Ab and a-synuclein, in particular the
annular and small spherical species (Fig. 2c). Thus, these species have been designated SOD1
protoﬁbrils, yet they do not convert to ﬁbrils over several weeks of incubation (Ray et al. 2004).
4.1.5 Prion protein (Creutzfeldt–Jakob disease, bovine spongiform encephalopathy, etc.)
The prion diseases [Creuzfeldt-Jakob disease (CJD), Gertsmann-Straussler syndrome (GSS), and
fatal familial insomnia (FFI) in humans, bovine spongiform encephalopathy (BSE) in cattle,
scrapie in sheep, and chronic wasting disease in elk] are characterized by the presence of an
abnormal form of the PrP in the brain. The ability of these diseases to be transmitted, apparently
by an abnormal form of the PrP, distinguishes them from the others discussed here, but there are
also sporadic forms of human prion disease as well as forms that are purely genetic ; caused by
mutations in the gene encoding PrP (CJD, GSS, and FFI). The disease-associated form of the
PrP, or PrP-Sc, is resistant to proteolysis and rich in b-sheet structure, relative to the normal
form of the PrP, PrP-C (Cohen & Prusiner, 1998). PrP-Sc can also be isolated in ﬁbrous form
(Rubenstein et al. 1987). However, several lines of evidence suggest that PrP-Sc, like other
amyloid ﬁbrils, may not be the neurotoxic form of the protein. Transgenic mice that over-
produce a disease-associated form of PrP exhibit disease-like phenotypes before PrP-Sc can be
detected (Chiesa & Harris, 2001 ; Harris et al. 2003). During this phase, the protease-resistance of
PrP gradually increased, suggesting the stepwise formation of structured oligomers of increasing
stability. In vitro ﬁbrillization of a fragment of PrP (residues 89–231) involves multiple oligomeric
species, some of which appear to be oﬀ-pathway b-sheet-rich oligomers (Baskakov et al. 2002).
Truncated variants of PrP form spherical and elongated protoﬁbril-like structures that share
properties with PrP-Sc and are capable of seeding the conversion of PrPC into amyloid ﬁbrils
(Lee & Eisenberg, 2003). Finally, a truncated variant of PrP (SHaPrP 90-232) forms spherical
and annular oligomeric structures in vitro, similar to those formed by Ab and a-synuclein
(Sokolowski et al. 2003). It was estimated that 8 subunits of SHaPrP 90-232 are required to form
the b-sheet-rich annular structures (Sokolowski et al. 2003).
4.1.6 Huntingtin (Huntington’s disease)
Huntington’s disease is the most prevalent of a group of purely genetic neurodegenerative
movement disorders that are caused by expansions of naturally occurring polyglutamine (polyQ)
tracts in several proteins (the normal function of these tracts is not known) (Zoghbi & Orr,
2000). The magnitude of the expansion is related to the age of onset of the disease, with large
expansions causing juvenile onset disease. The Huntington’s disease brain is characterized by
nuclear inclusions comprising the protein huntingtin (htn). Truncated mutant versions of htn
with expanded polyQ repeat form spherical (Poirier et al. 2002 ; Wacker et al. 2004) chain-like
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(Poirier et al. 2002), and annular (Wacker et al. 2004) protoﬁbrillar structures in vitro that closely
resemble those discussed above.
4.2 Amyloidogenic proteins that are not linked to disease also from pore-like protofibrils
Several other proteins that are not associated with disease form annular protoﬁbrillar structures
during the in vitro formation of amyloid ﬁbrils. Conditions required to induce annular protoﬁbrils
vary depending on the precursor protein. Under partial denaturing conditions, the calcium-
binding protein equine lysozyme (EL) self-assembles into protoﬁbrils and ﬁbrils of various
morphologies in a pH and calcium dependent manner (Malisauskas et al. 2003). At pH 45 and
57x in the presence of 10 mm EDTA, EL forms annular structures with an average diameter of
45 nm (¡5 nm), whereas at pH 20 EL forms rings with larger diameters ranging from
70–80 nm. Interestingly, in the presence of calcium at pH 45, elongated chain like structure are
populated as the major species, but upon removal of calcium, EL forms predominantly annular
structures (major species by AFM). Similarly, partial denaturing conditions were suﬃcient to
induce oligomerization and formation of pore-like structures by the core domain of the tumor
suppressor protein p53C (Ishimaru et al. 2003). Furthermore, Glabe & Kayed reported to have
developed conditions for the formation of highly homogeneous preparations of annular proto-
ﬁbrils (outer diameter 8–12 nm, inner diameter 18–45 nm) from several amyloidogenic proteins,
including Ab, a-synuclein, IAPP, polyglutamine (KKQ40KK), Prion H1 (106–126), TTR and
several Ab variants (Kayed & Glabe, 2004). It has been proposed that the ability of a wide range
of proteins to form annular protoﬁbrils suggest that these quaternary structures might represent
a second generic form of amyloid structures in addition to amyloid ﬁbrils (Malisauskas et al.
2003). Furthermore, the ability to populate pore-like structures as the predominant species in vitro
by manipulating solution conditions, suggest that in vivo conditions that promote the formation
of these structure could exist.
4.3 Amyloid proteins form non-fibrillar aggregates that have properties of protein channels
or pores
Disruption of Ca2+ homeostasis and generation of reactive oxygen species have long been re-
cognized to be key events in the pathogenesis of several neurodegenerative diseases, including
AD (Hardy & Higgins, 1992). Cellular factors responsible for initiating these events and the
mechanism by which they contribute to the neurodegeneration and cytotoxicity remain poorly
understood.
Every protein that forms amyloid ﬁbrils in vitro does so via the protoﬁbril. Aggregates com-
prising many of these proteins have channel-like or pore-like properties in vitro (the most relevant
studies are summarized below). We propose that the pore-like properties arise from the pore-like
protoﬁbrillar structures or the ability of a protoﬁbrillar intermediate to form these structures
upon interactions with membranes. We prefer the term pore as opposed to channel, because the
latter implies selectivity and regulation and we do not expect that either is involved with amyloid
associated diseases. However, the terms used in the sections below reﬂect literature usage.
4.3.1 Ab ‘ channels ’
In 1993, Arispe and colleagues demonstrated that Ab forms calcium channels in lipid bilayers
and proposed that channel formation by Ab is partially or wholly responsible for Ab-induced
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toxicity in AD (Arispe et al. 1993a, b). This ﬁnding has been reproduced many times, in several
diﬀerent laboratories, using many membrane models (Arispe et al. 1993b, 1994 ; Kawahara et al.
1997, 2000 ; Sanderson et al. 1997 ; Rhee et al. 1998 ; Hirakura et al. 1999; Lin et al. 1999, 2001 ;
Bhatia et al. 2000 ; Kourie et al. 2001b; Kagan et al. 2002 ; Lin & Kagan, 2002 ; Bahadi et al. 2003a ;
Alarcon et al. 2006). The form of Ab that is closely linked to AD pathogenesis (Ab42) exhibits
higher propensity to form channels, consistent with its increased propensity to aggregate and
form annular protoﬁbrils in vitro (H. Lashuel & P. T. Lansbury Jr., unpublished observations) as
compared to Ab40, the predominant form ( Jarrett et al. 1993). b-sheet formation is also linked to
Ab-channel formation (and aggregation) (Sanderson et al. 1997). When incorporated into arti-
ﬁcial lipid bilayers, Ab produces uniform pore-like structures with an outer diameter of 8–12 nm
and inner diameter of 2 nm (Fig. 3a, c) (Lin et al. 2001 ; Quist et al. 2005). These aggregates,
formed at the membrane surface, resemble, pore-like aggregates formed in solution using Ab42
or the disease-associated mutant form of Ab40 (E22G) (Lashuel et al. 2002b, 2003). Addition of
Ab40 oligomers to hypothalamic GT1-7 neuronal cells results in simultaneous formation of Ca2+
channels and increase in intracellular Ca2+ levels, suggesting that Ab40 oligomers is capable of
disrupting biological as well as artiﬁcial membranes, possibly via pore formation (Kawahara &
Kuroda, 2001, 2000 ; Singer & Dewji, 2006). The nature of the oligomer responsible for this
activity was not investigated. AD-derived Ab oligomers were observed to exhibit high aﬃnity
and selective attachment to membranes, suggesting that AD-derived oligomers are either directly
integrated into the membranes or bind tightly to other cell surface molecules of cultured hip-
pocampal neurons (Gong et al. 2003). Oligomer-speciﬁc antibodies were shown to block their
interaction with membranes.
4.3.2 a-Synuclein ‘pores ’
The a-synuclein protoﬁbril (but not the monomer or the ﬁbril) binds very strongly to vesicle
membranes and causes leakage of small compounds (less than y25 nm hydrodynamic radius)
entrapped within synthetic vesicles (Volles et al. 2001 ; Volles & Lansbury, 2002). This typical
pore-like behavior was consistent with the observation that addition of spherical protoﬁbrils of
a-synuclein to puriﬁed brain-derived vesicle (BDV) fractions resulted in the formation of pore-
like structures (Fig. 3b) (Ding et al. 2002). Additionally, reconstitution of a-synuclein in lipid
bilayers also results in the formation of pore-like structures that exhibit channel-like properties
(Quist et al. 2005). Mutations linked to familial PD promoted the formation of the b-sheet-rich
annular, pore-like (d=8–12 nm, 2–25 nm inner diameter) structures in solution (Lashuel et al.
2002a, b). These structures resembled in morphology and dimension, membrane-spanning pores
that are formed by protein toxins (e.g. hemolysin, latrotoxin, and aerolysin) (Valeva et al. 1997 ;
Orlova et al. 2000 ; Wallace et al. 2000). Vesicle permeabilization was also demonstrated for
protoﬁbrils comprising the congener c-synuclein, but not those comprising b-synuclein (Park &
Lansbury, 2003). At the same time, c-synuclein, but not b-synuclein, produced pore-like
structures in solution (H. Lashuel, unpublished results), strengthening the case that the pore-like
structures are responsible for the pore-like behavior of a-synuclein.
4.3.3 PrP ‘channels ’
Aguzzi and colleagues have proposed that the pathogenicity of the PrP may be related to
abnormal pore formation (Moore et al. 1999 ; Rossi et al. 2001 ; Behrens & Aguzzi, 2002).
This proposal, based on studies of a PrP homolog, Doppel, is supported by circumstantial
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experimental evidence. First, an abnormal transmembrane (translocation-incompetent) form of
PrP has been linked to disease (Hegde et al. 1999). Second, a peptide based on the proposed
transmembrane domain of PrP produce non-ﬁbrillar aggregates that disrupt membranes (Pillot
et al. 1997) and induce toxicity in rat cortical neurons (Pillot et al. 2000). Third, several PrP-based
peptides interacts with lipid membranes and form ion channels (Lin et al. 1997 ; Kourie &
Culverson, 2000 ; Bahadi et al. 2003b, c). Fourth, a truncated form of PrP permeabilizes synthetic
vesicles (Sanghera & Pinheiro, 2002). Fifth, when disease-associated mutant forms of PrP were
expressed in CHO cells, PrP was found to be very tightly associated with plasma membranes
(Lehmann & Harris, 1996).
4.3.4 Polyglutamine ‘channels ’
Peptides with pathological polyglutamine repeats (>35–40 residues) insert into artiﬁcial mem-
branes (Hirakura et al. 2000a ; Monoi et al. 2000 ; Kagan et al. 2001) and also aﬀect mitochondrial
Ca2+ homeostasis (Panov et al. 2002). Furthermore a polyglutamine (Gln40) peptide produced
homogeneous pore-like protoﬁbrillar structures in vitro, while a shortened peptide did not
(Monoi et al. 2000). Importantly, b-sheet formation, oligomerization, amyloid pore/channel
formation, and ﬁbrillogenesis are also very sensitive to polyGln repeat length (Scherzinger et al.
1999). Circumstantial evidence suggests that membrane disruption is mediated by direct inter-
action between the polyglutamine repeats or an aggregated form of these proteins resulting in the
formation of ion channels in lipid bilayers and in mitochondrial membranes. Interestingly, only
pathological polyglutamine repeat (>35–40) were observed to insert into artiﬁcial membranes
and exhibited direct eﬀects on mitochondrial Ca2+ homeostasis, reproducing the mitochondrial
deﬁcit seen in Huntington’s disease patients and in transgenic animals expressing these repeats
(Hirakura et al. 2000a ; Monoi et al. 2000 ; Kagan et al. 2001 ; Panov et al. 2002). Furthermore,
Kayed & Glabe (2004) reported that a polyglutamine protein containing 40 repeat (KKQ40KK)
forms homogeneous annular pore-like protoﬁbrillar structures in vitro, suggesting that protoﬁbril
formation and channel activity are linked.
Monoi and colleagues proposed that a single chain of poly-glutamine polypeptide is capable of
forming cylindrical pores by forming a right handed helix (62 residues/turn), termed m-helix,
that is further stabilized by backbone side-chain hydrogen bonding interactions between the
amide groups and glutmaine side-chain (Monoi, 1995 ; Monoi et al. 2000). What makes this model
an attractive one is that it oﬀers an explanation for the requirement of>35 polyglutamine tract
to confer pathogenecity in polyglutamine diseases, because 37 residues (each contributing 081 A˚
to the length) would be required to form a m-helix that spans the hydrophobic region of the
bilayer (30 A˚). A normal transmembrane domain composed of an a-helix is y20 amino acids
long. However, b-sheet formation, oligomerization and ﬁbrillogenesis by poly-glutamine pro-
teins are highly dependent on the polyQ repeat length with 36 or more glutamines favoring these
tertiary and quaternary structure changes (Scherzinger et al. 1999). However, further studies are
required to elucidate the nature of the membrane active species responsible for polyglutamine
membrane disruption properties.
4.4 Nature uses b-strand-mediated protein oligomerization to construct pore-forming toxins
A simple working hypothesis emerging from the studies summarized above holds that ﬁve prop-
erties of disease-associated amyloid proteins are linked: (1) aggregation, (2) b-sheet formation,
Cause of amyloid diseases 183
(3) amyloid pore formation, (4) membrane permeabilization, and (5) toxicity (see Fig. 4). This
proposal is more compelling because natural protein toxins utilize an analogous mechanism.
Latrotoxin, a-hemolysin, and aerolysin all form well-ordered, oligomeric membrane-spanning
pores characterized by b-sheet structure. It is important to remember that while these toxins are
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Fig. 4. Schematic depiction of the various steps involved in a-synuclein aggregation and Lewy Body
formation and potential mechanisms by which these processes could contribute to the pathogenesis of PD.
Several factors have been shown to play a role in initiating and/or accelerating a-synuclein aggregation and
ﬁbrillogenesis including, increased protein expression, mutations, oxidative stress induced modiﬁcations
and crosslinking, and phosphorylation at S129 (Chen & Feany, 2005; Fujiwara et al. 2002 ; Smith et al. 2005).
The scheme depicts amyloid protoﬁbril as the toxic species and that it may amplify itself by inhibiting
proteasome-dependent protein degradation, disrupting dompaniergic vesicles, formation of reactive oxygen
species and increased oxidative stress, causing mitochondrial dysfunction (Abou-Sleiman et al. 2006), all of
which have the aﬀect of increasing levels of a-synuclein and/or accelerating a-synuclien oligomerization
and protoﬁbril formation. This hypothesis is supported by the ﬁndings that triplication of the a-synuclein
gene causes and autosomal dominant PD in Iowan kindred (Singleton et al. 2003). Protoﬁbrils may promote
their own accumulation and toxicity by inhibiting the proteasome. Two gene products in the protein
degradation pathway have been implicated in early onset forms of PD (Lansbury & Brice, 2002). One form
is associated with genetic mutations in the gene encoding parkin (a protein with an E3 (ubiquitin ligase)-like
activity), where the mutations reduce or abolish parkin’s E3-like ligase activity (Kitada et al. 1998). A rare
point mutation in the gene encoding ubiquitin C-terminal hydrolase (UCH-L1), a neuronal-speciﬁc deubi-
quitinating enzyme, is thought to lead to reduced catalytic activity of UCH-L1, and, thus, indirectly aﬀect the
proteasomal function (Leroy et al. 1998). Furthermore, reduced expression of UCH-L1 in the substantia
nigra of DLB and PD brains suggest that it plays a role in modulating protein ag gregation and LB
formation (Barrachina et al. 2005). In addition to its beneﬁcial hydrolase activity (hydrolysis of C-terminal
ubiquityl esters and amides), UCH-L1 exhibits a concentration dependent ubiquityl ligase activity that is
thought to be pathogenic for PD. Taking together, these ﬁndings demonstrate that accumulation of
a-synuclein either due to increased expression or decreased degradation is suﬃcient to cause PD, as
predicted by the amyloid hypothesis.
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optimized by evolution to permeabilize target membranes, amyloid pore formation is likely to be
an accident and will therefore be very ineﬃcient in vitro. Pore formation by b-sheet bacterial
toxins involves a series of complex events that include membrane association, oligomerization,
and insertion of a b-barrel. The pore-forming protein toxins (PFTs) typically exist as structured,
water-soluble monomers ; conversion into the membrane-inserted pore requires that these pro-
teins undergo oligomerization and a conformational change. In the case of aerolysin, proteolytic
processing by the target is required to initiate the formation of the transmembrane b-barrel
domain (Abrami et al. 1998). The PFT proteins typically aggregate and/or are activated (Walker
et al. 1992 ; Song et al. 1996; Sellman et al. 1997 ; Heuck et al. 2003) at the membrane surface, a
feature that promotes membrane selectivity. Up to 100 b-hairpins can be inserted on activation,
to produce the transmembrane b-sheet pore (Hotze et al. 2001). b-barrels that span the
membrane (Valeva et al. 1997 ; Heuck et al. 2001) typically comprise 8–22 b-strands (each 10 13
residues long) and have an average diameter of 15–35 nm (Heuck et al. 2001, 2003). In the
a-hemolysin barrel, each monomer contributes an amphipathic hairpin to a 14-stranded hepta-
meric b-barrel (Menestrina et al. 2001). PFTs form pores ranging in diameter from 1 to 2 nm for
staphylococcal a-hemolysin (Fussle et al. 1981) and Vibrio cholerae cytolysin (Zitzer et al. 1995),
and from 15 to 45 nm for streptolysin O (Sekiya et al. 1993) and perfringolysin O (Olofsson et al.
1993). For some PFTs, some degree of heterogeneity (pore size and oligomeric state) has been
reported (Sharpe & London, 1999 ; Tadjibaeva et al. 2000). PFT membrane binding and oligomer-
ization are dependent on the membrane composition and microenvironment and, in some cases,
are mediated by interaction with receptor molecules. Cholesterol, for example, can play a critical
role in PFT insertion (Cabiaux et al. 1997), and may also play a role in amyloid pore toxicity
(Arispe & Doh, 2002 ; Curtain et al. 2003 ; Eckert et al. 2003).
5. Mechanisms of protofibril induced toxicity in protein aggregation diseases
5.1 The amyloid pore can explain the age-association and cell-type selectivity of the
neurodegenerative diseases
Most cases of AD, PD and ALS are sporadic, that is, they do not involve mutant protein, and are
strongly age-associated. Any model for pathogenesis must explain these cases. It is important to
emphasize that the wild-type proteins will also form amyloid pores in vitro, albeit more reluctantly
than the disease-associated mutants (Hafner et al. 2001; Ding et al. 2002 ; Lashuel et al. 2002a, b,
2003 ; Shtilerman et al. 2002 ; Chromy et al. 2003 ; Chung, 2003 ; Klug et al. 2003 ; Kayed & Glabe,
2004). Factors other than mutations could trigger pore formation pathogenesis in sporadic dis-
ease (Fig. 4). These factors could include (but are not limited to) : (1) increased expression of the
amyloid-forming protein (Singleton et al. 2004 ; Uryu et al. 2003) ; (2) impaired degradation of the
monomeric protein by the proteasome (Giasson & Lee, 2003) ; (3) impaired degradation of
the protoﬁbrils by a lysosome-mediated autophagic process (Lee et al. 2004) ; (4) changes in
chaperone activity and/or expression of homologs that act as speciﬁc chaperones (Rochet et al.
2000 ; Conway et al. 2001 ; Hashimoto et al. 2001 ; Masliah & Hashimoto, 2002) ; (5) changes in
levels of post-translational modiﬁcation, both enzymatic (Shimura et al. 2001 ; Fujiwara et al.
2002 ; Chen & Feany, 2005 ; Smith et al. 2005) and non-enzymatic (Conway et al. 2001) ; (6)
changes in the pathogenic microenvironment (pH, membrane composition, increased oxi-
dation). Oxidative damage of amyloid-forming proteins increases their propensity to misfold and
aggregate in vitro (Rakhit et al. 2002 ; Dauer & Przedborski, 2003). Expression of a-synuclein in
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cells, under oxidizing conditions, promotes cytoplasmic aggregation and cell death (Kim et al.
2003 ; Smith et al. 2005). Many of the factors listed above are ATP-dependent and would
therefore be expected to emerge on aging (Heydari et al. 1995 ; Gaczynska et al. 2001 ; Soti &
Csermely, 2002 ; Ferrington et al. 2005 ; Chondrogianni, 2005), when ATP production becomes
less eﬃcient. Aging may also aﬀect the susceptibility of membranes to permeabilization;
age-dependent changes in the distribution of cholesterol in neuronal membranes can facilitate
oligomerization and accumulation of Ab in plasma membranes (Wood et al. 2002) and choles-
terol content inﬂuences Ab toxicity in cell culture (Arispe & Doh, 2002). It must be emphasized
that of the factors listed above, all except membrane composition can be easily rationalized by
other pathogenic mechanisms.
Another striking feature of the neurodegenerative diseases is that they are selective for certain
neuronal populations (hence the clinical diversity). This feature can be explained by an amyloid
pore model. It is likely that structural diﬀerences among protoﬁbrils formed by the various
amyloid-forming proteins would confer some speciﬁcity in the way they interact with cellular
membranes. In addition, accessory molecules could play a role in modulating pore formation.
Finally, conversion of annular protoﬁbrils into amyloid pores may occur at the membrane sur-
face in vivo, triggered by speciﬁc environmental factors, changes in ﬂuidity of the membrane or
interaction with speciﬁc proteins. For example, the selective vulnerability of dopaminergic neur-
ons of the substantia nigra to a-synuclein toxicity in PD may be related to (1) the relatively low
expression of b-synuclein (Rockenstein et al. 2001), a homolog that prevents a-synuclein pro-
toﬁbril formation in vitro (Park & Lansbury, 2003), (2) the high concentration of cytoplasmic
dopamine (Lotharius & Brundin, 2002 ; Xu et al. 2002) in these cells (some populations of
dopaminergic neurons, that have more eﬃcient machinery for removal of cytoplasmic dopa-
mine, are resistant to PD), or (3) highly oxidizing conditions (higher levels of free radical scav-
engers are expressed in PD-resistant populations of dopaminergic neurons) (Hirsch et al. 1997),
A combination of the latter two factors may generate dopamine ortho-quinone, which, in vitro,
covalently modiﬁes a-synuclein and stabilizes protoﬁbrils (Conway et al. 2001 ; Li et al. 2004). The
extreme sensitivity of dopaminergic neurons to proteasomal inhibition (McNaught et al. 2002)
may be related to the importance of keeping cytoplasmic a-synuclein levels low in these cells.
Second, the diﬀerences between cell-types would be expected to inﬂuence the speciﬁc activity of
the amyloid pores in a way that depended on the protein constituent. Microinjection of proto-
ﬁbrillar Ab42 induces death of human neurons, but not neuroblastoma cells, astrocytes or other
non-neuronal cell lines (Zhang et al. 2002). Decreased susceptibility to intracellular toxicity could
arise from the absence of ‘ receptor ’ molecules that mediate Ab toxicity, the presence of neu-
roprotective factors, or just the changed composition of target membranes.
5.2 Protofibrils may promote their own accumulation by inhibiting the proteasome
Neurons have developed housekeeping systems to avoid misfolded proteins accumulating in the
cytoplasm. These include the chaperone system [some of which is ATP-dependent and would be
compromised on aging (Heydari et al. 1995 ; Soti & Csermely, 2002)], which prevents aggregation
(Muchowski, 2002 ; McClellan et al. 2005) and the proteasomal system, which degrades misfolded
and damaged proteins (Berke & Paulson, 2003 ; Ross & Pickart, 2004). The importance of
ubiquitin-dependent proteasomal degradation in PD is illustrated by the fact that parkin and
UCH-L1, two PD-linked gene products, are involved in this process (Lansbury & Brice, 2002)
(Fig. 4). Once protein aggregation has occurred, several backup systems may take over, including
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the HSP90 heat-shock protein, that is capable of disaggregating these species (Ben-Zvi &
Goloubinoﬀ, 2001 ; Ben-Zvi et al. 2004), the autophagy system, which engulfs and degrades
protein aggregates [including protoﬁbrils (Lee et al. 2004)] via fusion with the lysosome, and the
‘aggresome’ system (Kopito, 2000). Complete or partial failure of any of these systems could
have detrimental consequences for the cell. Convergent evidence indicates that the protoﬁbrils
themselves could compromise proteasomal degradation. First, overexpression of disease-
associated proteins (SOD1 or a-synuclein) in non-neuronal cells resulted in inhibition of pro-
teasome activity (Tanaka et al. 2001 ; Urushitani et al. 2002). Second, aggregated (protoﬁbrillar and
ﬁbrillar) a-synuclein binds directly to the proteasome and inhibits proteasomal activity (Snyder
et al. 2003 ; Lindersson et al. 2004). Third, inhibition of the neuronal proteasome causes cytosolic
inclusion formation (Ma & Lindquist, 2002) and neuronal death (Ma et al. 2002). It is not known
whether neuronal death is a result of an increase in protein aggregation due to decreased
degradation or of another proteasome-mediated event (Bennett et al. 2005). The former scenario
oﬀers a mechanism whereby toxicity can amplify itself.
6. Testing the amyloid pore hypothesis by attempting to disprove it
In the past 4 years, 18 diﬀerent amyloid-forming proteins have been reported to form preﬁbrillar
intermediates with pore-like morphologies (Table 1), supporting the notion that formation of the
pore and formation of the ﬁbril are tightly linked. However, whether the pore has any relevance
to disease, as proposed here, is not at all clear. It must be emphasized that there is a much work
to be done to strengthen the case, which must, by deﬁnition, be based on circumstantial
evidence. A goal of this review is to encourage experiments designed to disprove the hypothesis.
In closing, we make three points, each based on diﬀerent experimental approaches :
(1) Detection of amyloid pores in tissue from patients or animal models does not support the hypothesis nor does
the failure to detect these structures disprove it. This point is illustrated by the ﬂawed logic that led to
the toxic ﬁbril hypothesis. However, one could argue that, in the absence of evidence for the
existence of pores in tissue, there is no proof that they are able to form under physiological
conditions. Several studies of a-synuclein aggregates extracted from brains aﬀected by rare
neurodegenerative diseases related to PD, provide tantalizing evidence that pore-like struc-
tures do exist in vivo. Several studies of a-synuclein ﬁbrils from diﬀuse Lewy body disease
(DLBD) reveal pore-like structures that co-purify with a-synuclein ﬁbrils (Spillantini et al.
1998a ; Fujiwara et al. 2002). The resemblance of these structures to the amyloid pores pro-
duced from a-synuclein in vitro (Lashuel et al. 2002a) is striking. Direct evidence for the
existence of amyloid pore-like structures in vivo has been provided by the extraction of
annular a-synuclein structures, similar to those seen in in vitro preparations, from inclusions
from post-mortem brain tissues of a multiple system atrophy (MSA, another a-synuclein
aggregation disease) patient (Pountney et al. 2004).
(2) Evidence for membrane abnormalities is consistent with the amyloid pore, but these abnormalities could easily
have arisen by another mechanism. Formation of unregulated pores at the mitochondrial mem-
brane could result in altered Ca2+ homeostasis, the release of cytochrome c and other proa-
poptotic molecules, ultimately causing increased oxidative stress and apoptosis. These are
features that are clearly seen in the motor neurons of the post-mortem ALS brain, where
mitochondrial swelling and cytochrome c release are invariant features (Menzies et al. 2002).
In cellular models of PD, Golgi fragmentation, which is a common feature of human
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neurodegenerative diseases, including PD, AD, ALS, CJD, is speciﬁcally linked to protoﬁbril
formation (Gosavi et al. 2002).
(3) Determination of the toxicity of a mutant protein that eﬃciently forms very stable pores would be very
informative. According to the amyloid pore hypothesis, mutations in amyloid proteins that
stabilized pores to a great extent may have been disfavored by natural selection, since they
would have led to juvenile-onset disease. If one could discover a mutation that had this eﬀect
in vitro, one could then determine its toxicity relative to disease-linked mutants in cellular
and/or animal models of disease. If such a mutant lacked in vivo toxicity, then the amyloid
pore hypothesis would be untenable. If such a mutant was extremely toxic, the circumstantial
case would be considerably stronger. We are working hard to ﬁnd such a mutant. Hopefully,
the identiﬁcation of the pathogenic species will motivate drug discovery eﬀorts aimed at
treating the neurodegenerative processes that underlie these devastating diseases.
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